|
Aug 1
|
Stock market today: Dow edged higher but S&P stumbled after deluge of earnings
|
|
Aug 1
|
S&P 500 stumbles pressured by cruise stocks as earnings season heats up
|
|
Aug 1
|
Merck revenue rises, Pfizer hit by falling COVID product demand
|
|
Aug 1
|
Midday movers: Arista Networks, Caterpillar, ZoomInfo Technologies and more
|
|
Aug 1
|
Merck Posts Narrower-Than Expected Loss, Lifts Sales Outlook on Keytruda Boost
|
|
Aug 1
|
UPDATE 3-Merck raises 2023 sales forecast as top drugs beat Street estimates
|
|
Aug 1
|
Merck beats quarterly sales estimate on top drugs' strength
|
|
Aug 1
|
Merck posts narrower-than-expected loss as sales of top drugs beat Street estimates
|
|
Aug 1
|
Merck Announces Second-Quarter 2023 Financial Results
|
|
Jul 29
|
11 Best Magic Formula Stocks to Buy Now
|
|
Jul 28
|
Merck Announces Phase 3 KEYNOTE-756 Trial Met Primary Endpoint of Pathological Complete Response (pCR) Rate in Patients With High-Risk, Early-Stage ER+/HER2- Breast Cancer
|
|
Jul 28
|
Drugmakers go under the skin, skirting early US Medicare price negotiations
|
|
Jul 28
|
FOCUS-Drugmakers go under the skin, skirting early US Medicare price negotiations
|
|
Jul 28
|
13 Safe Stocks To Invest In
|
|
Jul 28
|
20 Countries With Highest Rates of Cancer
|
|
Jul 27
|
Merck Announces V116, an Investigational, 21-valent Pneumococcal Conjugate Vaccine Specifically Designed for Adults, Met Key Immunogenicity and Safety Endpoints in Two Phase 3 Trials
|
|
Jul 27
|
20 Countries With Highest Rates Of AIDS
|
|
Jul 26
|
Merck (MRK) to Report Q2 Earnings: What's in the Cards?
|
|
Jul 26
|
Merck and Moderna Initiate Phase 3 Study Evaluating V940 (mRNA-4157) in Combination with KEYTRUDA® (pembrolizumab) for Adjuvant Treatment of Patients with Resected High-Risk (Stage IIB-IV) Melanoma
|
|
Jul 25
|
Merck Announces Fourth-Quarter 2023 Dividend
|